Molecular Biology Reports

, Volume 40, Issue 11, pp 6351–6361 | Cite as

Expression of cell cycle regulatory factors hus1, gadd45a, rb1, cdkn2a and mre11a correlates with expression of clock gene per2 in human colorectal carcinoma tissue

  • Mária Štorcelová
  • Marián Vicián
  • Richard Reis
  • Michal Zeman
  • Iveta HerichováEmail author


Deregulated expression of clock gene per2 has previously been associated with progression of cancer. The aim of the present study was to identify genes related to per2 expression and involved in cell cycle control. Patients surgically treated for colorectal carcinoma with up-regulated and down-regulated per2 expression in cancer versus adjacent tissue were studied. Total RNA from cancer tissue of these patients was used to specify genes associated with altered per2 expression using the Human Cell Cycle RT2 profiler PCR array system. We identified seven genes positively correlated (hus1, gadd45α, rb1, cdkn2a, cdk5rp1, mre11a, sumo1) and two genes negatively correlated (cdc20, birc5) with per2 expression. Expression of these seven genes was subsequently measured by real time PCR in all patients of the cohort. Patients were divided into three groups according to TNM classification. We observed an increase in gene expression in cancer tissue compared to adjacent tissue in the first group of patients in all genes measured. Expression of genes positively associated with per2 gene expression was dependent on tumor staging and changes were observed preferentially in cancer tissue. For genes negatively associated with per2 expression we also detected changes in expression dependent on tumor staging. Expression of cdc20 and birc5 was increasing in the proximal tissue and decreasing in the cancer tissue. These results implicate functional involvement of per2 in the process of carcinogenesis via newly uncovered genes. The relevancy of gene expression for determination of diagnosis and prognosis should be considered in relation to tumor staging.


Circadian Sumo1 Cdk5rap1 Cdc20 Birc5 DNA damage 



This research was supported by Grants Slovak Research and Development Agency 0150-10 and 0291-12. The scientific grant agency of the Ministry of Education of the Slovak Republic and of the Slovak Academy of Sciences 1/1262/12.


  1. 1.
    Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106:2827–2836PubMedCrossRefGoogle Scholar
  2. 2.
    Mongrain V, Cermakian N (2009) Clock genes in health and diseases. J Appl Biomed 7:15–33Google Scholar
  3. 3.
    Berger J (2004) Regulation of circadian rhythms. J Appl Biomed 4:131–140Google Scholar
  4. 4.
    Stratmann M, Schibler U (2006) Properties, entrainment, and physiological functions of mammalian peripheral oscillators. J Biol Rhythms 21:494–506PubMedCrossRefGoogle Scholar
  5. 5.
    Berger J (2008) A two-clock model of circadian timing in the immune system of mammals. Pathol Biol 56:286–291PubMedCrossRefGoogle Scholar
  6. 6.
    Ko H, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15:R271–R277PubMedCrossRefGoogle Scholar
  7. 7.
    Guillaumond F, Dardente H, Giguère V, Cermakian N (2005) Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms 20:391–403PubMedCrossRefGoogle Scholar
  8. 8.
    Gachon F (2007) Physiological function of PARbZip circadian clock-controlled transcription factors. Ann Med 39:562–571PubMedCrossRefGoogle Scholar
  9. 9.
    Reischl S, Kramer A (2011) Kinases and phosphatases in the mammalian circadian clock. FEBS Lett 585:1393–1399PubMedCrossRefGoogle Scholar
  10. 10.
    Hirota T, Fukada Y (2004) Resetting mechanism of central and peripheral circadian clocks in mammals. Zool Sci 21:359–368PubMedCrossRefGoogle Scholar
  11. 11.
    Damiola F, Le Minli N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U (2000) Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 14:2950–2961PubMedCrossRefGoogle Scholar
  12. 12.
    Hara R, Wan K, Wakamatsu H, Aida R, Moriya T, Akiyama M, Shibata S (2001) Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. Genes Cells 6:269–278PubMedCrossRefGoogle Scholar
  13. 13.
    Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M (2001) Entrainment of the circadian clock in the liver by feeding. Science 291:490–493PubMedCrossRefGoogle Scholar
  14. 14.
    Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA (2003) Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst 95:825–828PubMedCrossRefGoogle Scholar
  15. 15.
    Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568PubMedCrossRefGoogle Scholar
  16. 16.
    Leonardi GC, Rapisarda V, Marconi A, Scalisi A, Catalano F, Proietti L, Travali S, Libra M, Fenga C (2012) Correlation of the risk of breast cancer and disruption of the circadian rhythm. Oncol Rep 28:418–428PubMedGoogle Scholar
  17. 17.
    Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50PubMedCrossRefGoogle Scholar
  18. 18.
    Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97:589–596PubMedCrossRefGoogle Scholar
  19. 19.
    Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, Wang Z, Ding JM (2007) Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14:815–818PubMedCrossRefGoogle Scholar
  20. 20.
    Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14:268–270PubMedGoogle Scholar
  21. 21.
    Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X, Zheng T (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin’s lymphoma. Int J Cancer 120:432–435PubMedCrossRefGoogle Scholar
  22. 22.
    Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, Sesterhenn I, Chokkalingam AP, Danforth KN, Shen MC, Stanczyk FZ, Gao YT, Hsing AW (2008) Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 11:342–348PubMedCrossRefGoogle Scholar
  23. 23.
    Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, Brown HN, Zheng T (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 107:421–425PubMedCrossRefGoogle Scholar
  24. 24.
    Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case–control study. Cancer Res 69:9315–9322PubMedCrossRefGoogle Scholar
  25. 25.
    Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y (2009) Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res 69:3605–3613PubMedCrossRefGoogle Scholar
  26. 26.
    Chen K, Dai H, Cao M, Song F, Wei Q, Zhang W (2009) The associations between polymorphisms of clock genes and the susceptibility to breast cancer. 100th Annual Meeting of the American Association for Cancer Research, AACR, Denver, CO, USAGoogle Scholar
  27. 27.
    Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y (2010) CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res 70:1459–1468PubMedCrossRefGoogle Scholar
  28. 28.
    Zeman M, Vician M, Monosíková J, Reis R, Herichová I (2008) Deregulated expression of the per2 gene in human colorectal carcinoma. Mol Med Rep 1:599–603PubMedGoogle Scholar
  29. 29.
    Wood PA, Yang X, Hrushesky WJM (2010) The role of circadian rhythm in the pathogenesis of colorectal cancer. Curr Colorectal Cancer Rep 6:74–82CrossRefGoogle Scholar
  30. 30.
    Wang Y, Hua L, Lu C, Chen Z (2011) Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. World J Surg Oncol 9:166PubMedCrossRefGoogle Scholar
  31. 31.
    Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255–259PubMedCrossRefGoogle Scholar
  32. 32.
    Gery S, Koeffler HP (2010) Circadian rhythms and cancer. Cell Cycle 9:1097–1103PubMedCrossRefGoogle Scholar
  33. 33.
    Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, Antoch MP, Walker JR, Esser KA, Hogenesch JB, Takahashi JS (2007) Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci USA 104:3342–3347PubMedCrossRefGoogle Scholar
  34. 34.
    Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1–11PubMedGoogle Scholar
  35. 35.
    Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM (2008) Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms 6:4PubMedCrossRefGoogle Scholar
  36. 36.
    Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ (2009) Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117:423–431PubMedCrossRefGoogle Scholar
  37. 37.
    Frank SA (2007) Dynamics of cancer: incidence, inheritance, and evolution. Princeton University Press, Princeton Stem cells: tissue renewalGoogle Scholar
  38. 38.
    Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T (2011) Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One 6:e20456PubMedCrossRefGoogle Scholar
  39. 39.
    van Wezel T, Middeldorp A, Wijnen JT, Morreau H (2012) A review of the genetic background and tumour profiling in familial colorectal cancer. Mutagenesis 27:239–245PubMedCrossRefGoogle Scholar
  40. 40.
    Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C (2003) The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3:695–701PubMedCrossRefGoogle Scholar
  41. 41.
    Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:316–323PubMedCrossRefGoogle Scholar
  42. 42.
    St Onge RP, Udell CM, Casselman R, Davey S (1999) The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein that forms complexes with hRAD1 and hHUS1. Mol Biol Cell 10:1985–1995PubMedCrossRefGoogle Scholar
  43. 43.
    Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196PubMedCrossRefGoogle Scholar
  44. 44.
    Hatanaka F, Matsubara C, Myung J, Yoritaka T, Kamimura N, Tsutsumi S, Kanai A, Suzuki Y, Sassone-Corsi P, Aburatani H, Sugano S, Takumi T (2010) Genome-wide profiling of the core clock protein BMAL1 targets reveals a strict relationship with metabolism. Mol Cell Biol 30:5636–5648PubMedCrossRefGoogle Scholar
  45. 45.
    Wang BX, Yin BL, He B, Chen C, Zhao M, Zhang WX, Xia ZK, Pan YZ, Tang JQ, Zhou XM, Yin N (2012) Overexpression of DNA damage-induced 45 alpha gene contributes to esophageal squamous cell cancer by promoter hypomethylation. J Exp Clin Cancer Res 31:11PubMedCrossRefGoogle Scholar
  46. 46.
    Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, Engelstein M, Friend SH, Henner WD, Gilmer TM, Kastan MB, Fornace AJ Jr (1994) Characterization of human Gadd45, a p53-regulated protein. J Biol Chem 269:32672–32677PubMedGoogle Scholar
  47. 47.
    Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K, Sakai T (2003) p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 22:7762–7773PubMedCrossRefGoogle Scholar
  48. 48.
    Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, Zhu Y (2010) Phenotypic effects of the circadian gene cryptochrome 2 on cancer-related pathways. BMC Cancer 10:110PubMedCrossRefGoogle Scholar
  49. 49.
    Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10:699–703PubMedCrossRefGoogle Scholar
  50. 50.
    Yamamoto H, Soh JW, Monden T, Klein MG, Zhang LM, Shirin H, Arber N, Tomita N, Schieren I, Stein CA, Weinstein IB (1999) Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin Cancer Res 5:1805–1815PubMedGoogle Scholar
  51. 51.
    Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001–5014PubMedCrossRefGoogle Scholar
  52. 52.
    Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O’Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939–2952PubMedCrossRefGoogle Scholar
  53. 53.
    Milly M, Konečný M, Závodná K, Weismanová E, Bartošová Z, Kaušitz J (2010) Hereditary form of malignant melanoma associated with mutations in CDKN2A gene. Onkologia 5:77–80Google Scholar
  54. 54.
    Zhang Y, Xiong Y (1999) Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3:579–591PubMedCrossRefGoogle Scholar
  55. 55.
    Lam AK, Ong K, Giv MJ, Ho YH (2008) p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 40:580–585PubMedCrossRefGoogle Scholar
  56. 56.
    Zhao P, Hu YC, Talbot IC (2003) Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9:2202–2206PubMedGoogle Scholar
  57. 57.
    Griniatsos J, Michail OP, Theocharis S, Arvelakis A, Papaconstantinou I, Felekouras E, Pikoulis E, Karavokyros I, Bakoyiannis C, Marinos G, Bramis J, Michail PO (2006) Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol 12:2109–2114PubMedGoogle Scholar
  58. 58.
    Ching YP, Pang AS, Lam WH, Qi RZ, Wang JH (2002) Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor. J Biol Chem 277:15237–15240PubMedCrossRefGoogle Scholar
  59. 59.
    Reiter V, Matschkal DM, Wagner M, Globisch D, Kneuttinger AC, Müller M, Carell T (2012) The CDK5 repressor CDK5RAP1 is a methylthiotransferase acting on nuclear and mitochondrial RNA. Nucleic Acids Res 40:6235–6240PubMedCrossRefGoogle Scholar
  60. 60.
    Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247–254PubMedCrossRefGoogle Scholar
  61. 61.
    Chang L, Liu YY, Zhu B, Li Y, Hua H, Wang YH, Zhang J, Jiang Z, Wang ZR (2009) High expression of the circadian gene mPer2 diminishes the radiosensitivity of NIH 3T3 cells. Braz J Med Biol Res 42:882–891PubMedCrossRefGoogle Scholar
  62. 62.
    Su HL, Li SS (2002) Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296:65–73PubMedCrossRefGoogle Scholar
  63. 63.
    Katayama A, Ogino T, Bandoh N, Takahara M, Kishibe K, Nonaka S, Harabuchi Y (2007) Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: possible involvement in tumor proliferation and prognosis. Int J Oncol 31:517–524PubMedGoogle Scholar
  64. 64.
    Peters JM (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7:644–656PubMedCrossRefGoogle Scholar
  65. 65.
    Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562–1571PubMedCrossRefGoogle Scholar
  66. 66.
    Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, Nita ME, Takagi T, Nakamura Y, Tsunoda T (2001) Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61:3544–3549PubMedGoogle Scholar
  67. 67.
    Vader G, Kauw JJ, Medema RH, Lens SM (2006) Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 7:85–92PubMedCrossRefGoogle Scholar
  68. 68.
    Cosgrave N, Hill AD, Young LS (2006) Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol 37:377–390PubMedCrossRefGoogle Scholar
  69. 69.
    Raj D, Liu T, Samadashwily G, Li F, Grossman D (2008) Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29:194–201PubMedCrossRefGoogle Scholar
  70. 70.
    Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRefGoogle Scholar
  71. 71.
    Lu C, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808–1812PubMedGoogle Scholar
  72. 72.
    Croner RS, Foertsch T, Brueckl WM, Guenther K, Siebenhaar R, Stremmel C, Matzel KE, Papadopoulos T, Kirchner T, Behrens J, Klein-Hitpass L, Stuerzl M, Hohenberger W, Reingruber B (2005) Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis 20:353–362PubMedCrossRefGoogle Scholar
  73. 73.
    Thompson LH, Schild D (2001) Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 477:131–153PubMedCrossRefGoogle Scholar
  74. 74.
    Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, van der Horst GT (2008) Phase resetting of the mammalian circadian clock by DNA damage. Curr Biol 18:286–291PubMedCrossRefGoogle Scholar
  75. 75.
    Gamsby JJ, Loros JJ, Dunlap JC (2009) A phylogenetically conserved DNA damage response resets the circadian clock. J Biol Rhythms 24:193–202PubMedCrossRefGoogle Scholar
  76. 76.
    Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85PubMedCrossRefGoogle Scholar
  77. 77.
    Weiss RS, Leder P, Vaziri C (2003) Critical role for mouse Hus1 in an S-phase DNA damage cell cycle checkpoint. Mol Cell Biol 23:791–803PubMedCrossRefGoogle Scholar
  78. 78.
    Smith ML, Chen IT, Zhan Q, Bae I, Chan CY, Gilmer TM, Kastan MB, O’Connor PM, Fornace AJ Jr (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376–1380PubMedCrossRefGoogle Scholar
  79. 79.
    Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O’Connor PM, Fornace AJ Jr, Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706–3711PubMedCrossRefGoogle Scholar
  80. 80.
    Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330PubMedCrossRefGoogle Scholar
  81. 81.
    Shapiro GI, Edwards CD, Ewen ME, Rollins BJ (1998) p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18:378–387PubMedGoogle Scholar
  82. 82.
    Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000PubMedCrossRefGoogle Scholar
  83. 83.
    Dimitrova N, de Lange T (2009) Cell cycle-dependent role of MRN at dysfunctional telomeres: ATM signaling-dependent induction of nonhomologous end joining (NHEJ) in G1 and resection-mediated inhibition of NHEJ in G2. Mol Cell Biol 29:5552–5563PubMedCrossRefGoogle Scholar
  84. 84.
    Olson E, Nievera CJ, Liu E, Lee AY, Chen L, Wu X (2007) The Mre11 complex mediates the S-phase checkpoint through an interaction with replication protein. A Mol Cell Biol 27:6053–6067CrossRefGoogle Scholar
  85. 85.
    Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD (2003) The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J 22:6610–6620PubMedCrossRefGoogle Scholar
  86. 86.
    Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRefGoogle Scholar
  87. 87.
    Enoch T, Carr AM, Nurse P (1992) Fission yeast genes involved in coupling mitosis to completion of DNA replication. Genes Dev 6:2035–2046PubMedCrossRefGoogle Scholar
  88. 88.
    Fornace AJ Jr (1992) Mammalian genes induced by radiation; activation of genes associated with growth control. Annu Rev Genet 26:507–526PubMedCrossRefGoogle Scholar
  89. 89.
    Wang JY, Knudsen ES, Welch PJ (1994) The retinoblastoma tumor suppressor protein. Adv Cancer Res 64:25–85PubMedCrossRefGoogle Scholar
  90. 90.
    Hay RT (2005) SUMO: a history of modification. Mol Cell 18:1–12PubMedCrossRefGoogle Scholar
  91. 91.
    Visintin R, Prinz S, Amon A (1997) CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science 278:460–463PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Mária Štorcelová
    • 1
  • Marián Vicián
    • 2
  • Richard Reis
    • 2
  • Michal Zeman
    • 1
  • Iveta Herichová
    • 1
    Email author
  1. 1.Department of Animal Physiology and Ethology, Faculty of Natural SciencesComenius University BratislavaBratislavaSlovak Republic
  2. 2.First Surgery DepartmentUniversity Hospital, Comenius University BratislavaBratislavaSlovak Republic

Personalised recommendations